<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1197">
  <stage>Registered</stage>
  <submitdate>30/03/2006</submitdate>
  <approvaldate>11/08/2006</approvaldate>
  <actrnumber>ACTRN12606000343505</actrnumber>
  <trial_identification>
    <studytitle>CHAMPION PCI</studytitle>
    <scientifictitle>A Clinical trial comparing Cangrelor 
to Clopidogrel in subjects who require percutaneous coronary intervention (PCI) to demonstrate that cangrelor is superior, or at least non-inferior, to that of clopidogrel as measured by a composite of all-cause mortality, myocardial infarction (MI) and ischaemia driven revascularisation (IDR).</scientifictitle>
    <utrn />
    <trialacronym>CHAMPION PCI</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Unstable Angina</healthcondition>
    <healthcondition>Myocardial Infarction</healthcondition>
    <healthcondition>Acute Coronary Syndromes</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects who fulfill the criteria and are to under go PCI will be randomised on a 1:1 randomisation to receive either 4 placebo capsules orally plus Cangrelor bolus (30ug/kg) &amp; infusion (4 ug/kg/min) for at least 2 hours or the duration of the procedure, whichever is longer.  Post infusion be administered 4 Clopidogrel capsules (600mg) orally once.  The other group would receive 4 Clopidogrel capsules (600mg) plus Placebo bolus (30 ug/kg) and infusion (4 ug/kg/min) for the duration of the procedure or 2 hours whichever is longer.  At the end of the infusion they will receive 4 placebo capsules once.  Clopidogrel maintenance is at the physicians discretion.</interventions>
    <comparator>Placebo</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All cause mortality</outcome>
      <timepoint>In the 48 hours after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Myocardial Infaction</outcome>
      <timepoint>In the 48 hours after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ischaemic driven revascularization</outcome>
      <timepoint>In the 48 hours after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All cause mortality and myocardial infarction</outcome>
      <timepoint>At 30 days.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnostic coronary angiography demonstrating atherosclerosis amenable to treatment by PCI with or without stent implantation and one of the following:
1. Non ST segment myocardial infarction with Troponin I or T greater than upper limit of normal within 24 hours of randomisation.
2. Unstable angina with ischaemic chest discomfort occurring at rest and lasting longer than 10 minutes within 24 hours of randomisation and with dynamic ECG changes with age greater than 65 years or diabetes.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Glycoprotein IIb/IIIa (GPI) Inhibitor usuage within the previous 12 hours.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone/fax</concealment>
    <sequence>Simple randomisation by using a randomisation table created by a computer software(ie computerised sequence generation).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Active control</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>23/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>9000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>The Medicines Company</primarysponsorname>
    <primarysponsoraddress>8 Campus Drive
Parsippany, NJ 07054</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>The Medicines Company</fundingname>
      <fundingaddress>8 Campus Drive
Parsippany, NJ 07054</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Flinders Medical Centre</sponsorname>
      <sponsoraddress>1 Flinders Drive
Bedford Park SA 5042</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Each year over 1 million patients globally undergo diagnostic angiography and are discovered to have atherosclerotic plaque amenable to percutaneous coronary intervention (PCI). This area has been extensively researched and benefit shown with the use of aspirin, and more recently 300mg loading dose and 75mg maintenance dose of clopidogrel. Despite the apparent benefit, many patients still do not receive a loading dose (either deliberately  as there is a reasonable probability of being triaged to CABG) or because there is insufficient time (stable patients undergoing diagnostic angiogram who proceed immediately to PCI). Cangrelor is a new drug being developed, which in early phase trials appears to be safe and well tolerated &amp; will provide platelet inhibition throughout the infusion with full recovery of platelet function within 60min of stopping the infusion.  This     trial aims to demonstrate the efficacy       of cangrelor compared to clopidogrel in patients requiring PCI. The primary endpoints to be measured will be all    cause mortality, myocardial infarction    (MI) and ischemia driven reinfarction   (IDR) at 48hrs and 1 month, then   mortality at 1year.  This study will     employ double blind and double dummy tachniques in addition to an active        control.  Subjects, Investigators, Study Monitor, Data Analyst and the sponsor   The Medicines Company will be blinded.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>TMC-CAN-05-02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>TMC-CAN-05-02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>TMC-CAN-05-02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Holy Spirit Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>TMC-CAN-05-02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The  Canberra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>TMC-CAN-05-02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>TMC-CAN-05-02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Derek Chew</name>
      <address>Cardiac Services
Flinders Medical Centre
Bedford Park SA 5042</address>
      <phone>+61 8 84042001</phone>
      <fax>+61 8 84042150</fax>
      <email>derek.chew@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Caroline Thomas</name>
      <address>Cardiology Research
Flinders Medical Centre
1 Flinders Drive
Bedford Park SA 5042</address>
      <phone>+61 8 82044440</phone>
      <fax>+61 8 82045000</fax>
      <email>c.thomas@flinders.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>